HealthDay News — Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term, according to a study published online January ...

Compared with currently available insulin secretagogues, DPP-4 inhibitors, by enhancing biologically active (intact) GLP-1, increase insulin secretion and suppress glucagon secretion in a glucose ...

Of over 350,000 adults with type 2 diabetes, thyroid cancer risk was significantly higher within the first year after GLP-1 agonist initiation compared with SGLT2 inhibitors, DPP-4 inhibitors ...

The enzyme dipeptidyl peptidase-4 (DPP-4) prevents the inactivation of glucagon-like peptide-1 (GLP-1). Since GLP-1-based therapy is a promising novel treatment of type 2 diabetes, the strategy to ...

The following is a summary of “Association between incretin-based drugs and risk of cholangiocarcinoma among patients with ...

Adults with type 2 diabetes using a GLP-1 receptor agonist have a similar risk for developing thyroid cancer as those using a ...

Citing follow-up data for up to 10 years, the researchers noted that out of 12,351 patients on GLP-1s, only 278 developed dementia. In contrast, 1,849 on DPP-4 inhibitors and 2,480 on sulfonylurea ...

DPP-4 inhibitor cases were generally older, more often male, and had lower rates of psychiatric disorders and obesity than GLP-1 RA cases. However, the association between DPP-4 inhibitor use and ...

analyzed Medicare data from 2017 through 2020 and compared GLP-1 users with SGLT-2 inhibitor and DPP-4 inhibitor users. Guo's group found that GLP-1 users didn't have an increased risk for ...

Adults with type 2 diabetes using a GLP-1 drug have a similar risk for thyroid cancer as those using other diabetes drugs, though increased thyroid cancer risk was observed in the first year after GLP ...

The San Diego–based company’s molecules avoid the well-trod GLP-1 pathway in favor of an alternate route in the gut.